Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.79 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18768488 | 1.00 | CTSS (0.79) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL12294147 | 0.95 | CTSS (0.71) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL19213211 | 0.95 | CTSS (0.71) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL8252057 | 0.95 | CTSS (0.71) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL1101653 | 0.95 | CTSS (0.71) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL8252068 | 0.95 | CTSS (0.71) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL12293859 | 0.94 | CTSS (0.80) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL851151 | 0.93 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL18768649 | 0.93 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL828774 | 0.93 | CTSS (0.82) | CTSSCTSBADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771339-B1 | IMPROVED PROCESS FOR PREPARING AN INTERMEDIATE OF THE MACROCYCLIC PROTEASE INHIBITOR TMC 435 | JANSSEN PHARMACEUTICALS INC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| US-9353103-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-05-31 | — | — | US | disclosed |
| US-8143402-B2 | Polymorphic forms of a macrocyclic inhibitor of HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-03-27 | — | — | US | disclosed |
| US-8143402-B2 | Polymorphic forms of a macrocyclic inhibitor of HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-03-27 | — | — | US | disclosed |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-12-01 | — | — | US | disclosed |
| EP-2322516-A1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | Tibotec Pharmaceuticals Ltd. (IE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100029715-A1 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029715-A1 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | JANSSEN SCIENCES IRELAND UC (IE) | 2010-02-04 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | MEDIVIR AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2008092954-A2 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-07 | — | — | WO | disclosed |
| WO-2007014926-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885CTSB 3370/4885ADRB3 2852/4885 |
| US-20090281140-A1 | Macrocyclic inhibitors of hepatitis c virus | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885CTSB 3370/4885ADRB3 2852/4885 |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | CTSS 39/4885CTSB 76/4885ADRB3 2178/4885 |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | CTSS 1949/4885CTSB 3370/4885ADRB3 2852/4885 |
| US-20100029715-A1 | POLYMORPHIC FORMS OF A MACROCYCLIC INHIBITOR OF HCV | HLA-DRB1, CYP3A43, HAVCR2 | CTSS 723/4885CTSB 438/4885ADRB3 2756/4885 |
| US-20110295012-A1 | Macrocyclic Inhibitors Of Hepatitis C Virus | CYP2A7, HCCS, CYP3A7 | CTSS 1858/4885CTSB 3274/4885ADRB3 2867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.